Ianalumab is a Monoclonal Antibody owned by Novartis, and is involved in 18 clinical trials, of which 4 were completed, 9 are ongoing, and 5 are planned.

VAY-736 is a monoclonal antibody directed against BAFF (B cell-activating factor belonging to the TNF family) receptor. BAFF binds to the BAFF-R and activates the nuclear factor-kappa B pathway and ultimately to the transcription of the anti-apoptotic factor Bcl-2. BAFF-R plays a fundamental role during the transition from immature T1 to T2 B cells. This leads to generation of mature B cells in the spleen which are capable of mounting immune response. It also promotes survival of antibody-producing B cells as they exit the bone marrow and also prevents apoptosis in later stages.

The revenue for Ianalumab is expected to reach a total of $257m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Ianalumab NPV Report.

Ianalumab was originated by Novartis and MorphoSys and is currently owned by Novartis.

Ianalumab Overview

Ianalumab is under development for the treatment of autoimmune hepatitis, chronic lymphocytic leukemia, primary Sjogren's syndrome, systemic lupus erythematosus, rheumatoid arthritis, idiopathic pulmonary fibrosis, B-Cell Non-Hodgkin Lymphomas including diffuse large B-cell lymphoma, follicular lymphoma (FL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), autoimmune hemolytic anemia, primary immune thrombocytopenia and lupus nephritis. The therapeutic candidate is administered through subcutaneous and intravenous routes. It is a monoclonal antibody that acts by targeting BAFF receptor (BAFF-R). The therapeutic candidate is based on HuCAL (human combinatorial antibody library) technology. It is a new molecular entity (NME).

The drug candidate was also under development for the treatment of relapsed or refractory chronic lymphocytic leukemia, pemphigus vulgaris and relapsing-remitting multiple sclerosis (RRMS).

Novartis Overview

Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.

The company reported revenues of (US Dollars) US$52,877 million for the fiscal year ended December 2021 (FY2021), an increase of 6% over FY2020. In FY2021, the company’s operating margin was 22.1%, compared to an operating margin of 20.3% in FY2020. In FY2021, the company recorded a net margin of 45.4%, compared to a net margin of 16.2% in FY2020. The company reported revenues of US$12,842 million for the third quarter ended September 2022, a decrease of 1.9% over the previous quarter.

Quick View – Ianalumab

Report Segments
  • Innovator
Drug Name
  • Ianalumab
Administration Pathway
  • Intravenous
  • Subcutaneous
Therapeutic Areas
  • Central Nervous System
  • Gastrointestinal
  • Hematological Disorders
  • Immunology
  • Oncology
  • Respiratory
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.